Free Trial

Abbvie 7Pt Jumbo Guidance Updated

PIPELINE

Headlines say the orderbook is over $80B at the moment. Updated guidance usually a sign the package should launch soon.

  • Date $MM Issuer (Priced *, Launch #)
  • 2/22 $Benchmark Abbvie** 3Y +35, 5Y +50, 7Y +60, 10Y +75, 20Y +75, 30Y +95, 40Y +105
  • 2/22 $2B *Federal Rep of Germany (KFW) 10Y +51
  • 2/22 $2B #BNG Bank 3Y SOFR +32
  • 2/22 $1B Royal Caribbean 8NC3
  • 2/22 $700M #Northern States WNG 30Y +97
  • 2/22 $Benchmark Caterpillar 2Y +35, 2Y SOFR+46, 5Y +55
  • 2/22 $Benchmark Exelon 5Y +87.5, 10Y +115, 29Y +130
  • 2/22 $Benchmark Panama 7Y 8%a, 13Y 8.5%a, 33Y 8.75%a
  • **Abbvie held investor calls yesterday after filing funding offer to fund Immunogen deal. According to Abbvie, the transaction was "valued at $31.26 per share in cash, for a total equity value of approximately $10.1B." For historical context, back on November 12, 2019, Abbvie issued $30B debt over 10 tranches, making it the fifth largest issuance on record.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.